The Internal Revenue Service started notifying companies that were awarded a tax credit or grant under the therapeutic discovery tax credit program. Of the more than 5,600 projects submitted, 4,606 applications from 2,923 companies received awards.

In a two-day meeting, the FDA heard concerns about follow-on biologics, including how to manage their labeling, determining biosimilarity, etc.

The Department of Justice filed an amicus brief in Association for Molecular Pathology v. USPTO arguing that DNA is not patent-eligible subject matter.